Inflammation After One Lung Ventilation
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02188407 |
Recruitment Status :
Completed
First Posted : July 11, 2014
Last Update Posted : July 11, 2014
|
- Study Details
- Tabular View
- Results Submitted
- Disclaimer
- How to Read a Study Record
The aim of the study was to prospectively investigate the influence of one-lung ventilation (OLV) on the inflammatory response and to identify possible antiinflammatory effects of the volatile anaesthetic sevoflurane.
Forty patients undergoing thoracic surgery with OLV were enrolled in this prospective, randomised study. The patients were randomly allocated into two groups to receive either propofol (Group P) or sevoflurane (Group S) for induction and maintenance of anaesthesia.
Inflammatory mediators (Interleukin 6 (IL6), Interleukin8 (IL8), Interleukin 10 (IL10), (C- reactive protein)CRP) were measured intra- and postoperatively.
Six hours after surgery oxygenation index (PaO2/FiO2) was calculated and chest X ray was taken and assessed.
The clinical outcome determinated by postoperative adverse events was assessed as the secondary endpoint.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Inflammation | Drug: Sevoflurane Drug: Propofol | Phase 1 |

Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 40 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Participant, Investigator) |
Primary Purpose: | Treatment |
Official Title: | Phase 1 Study of Antiinflammatory Effect of Sevoflurane in Open Lung Surgery With One-Lung Ventilation |
Study Start Date : | July 2008 |
Actual Primary Completion Date : | September 2013 |
Actual Study Completion Date : | January 2014 |

Arm | Intervention/treatment |
---|---|
Experimental: Sevoflurane
Sevoflurane group (S group)- The group anaesthesied with sevoflurane
|
Drug: Sevoflurane
MAC 3-5 V% during surgery
Other Name: Sevorane |
Active Comparator: Propofol
Propofol 4-6 mg/kg/h iv
|
Drug: Propofol
Propofol group (P group)- The group anaesthesied with propofol |
- IL 6 [ Time Frame: intraoperatively and 6 hours after surgery ]IL 6 blood level (ng/L) at the 1. Insertion of the retractor, 2. Begining of OLV 3. End of surgery, 4. Six hours after surgery
- IL8 [ Time Frame: intraoperatively , 6 hours after surgery ]IL 8 (mg/L) blood level at the 1. Insertion of the retractor, 2. Begining of OLV 3. End of surgery, 4. Six hours after surgery
- IL10 [ Time Frame: intraoperatively , 6 hours after surgery ]IL 10 blood level (ng/L) at the 1. Insertion of the retractor, 2. Begining of OLV 3. End of surgery, 4. Six hours after surgery
- CRP [ Time Frame: 24 hours after surgery ]CRP blood level 24 hours after surgery
- Oxygenation index [ Time Frame: 6h after surgery ]pO2/FiO2
- Lung infiltration [ Time Frame: 6h after surgery ]X-ray of the lung- clear lungs, partly infiltrated lungs, totally infiltrated lungs
- Postoperative adverse events [ Time Frame: 24h after surgery ]Prolonged antibiotics Pneumonia Reintubation SIRS ARDS Sepsis Death Acute Renal Failure Pooperative nausea and vomiting

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 20 Years to 70 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients aged 20-70 years
- American Society of Anaesthesiologists (ASA) physical status I-III
- elective open lobectomy with OLV
Exclusion Criteria:
- history of drug hypersensitivity
- drug addiction
- treatment with psychotropic drugs
- severe psychiatric and central nerve system diseases
- persistent tobacco abuse, autoimmune system diseases
- diabetes mellitus
- cardiac failure (New York Heart Association class greater than 2)
- clinically relevant obstructive and restrictive lung diseases (vital capacity or forced expiratory volume in 1s lover than 50% of the predicted values)
- pulmonary hypertension (mean pulmonary arterial pressure grater than 25 mmHg)
- pre-existing coagulation disorders
- history of treatment with immunosuppressant drugs in the 4 weeks before surgery
- Patient with evidence of pulmonary or systemic infections (C-reactive protein serum concentration greater than 5 mg/L, leucocytosis greater than 10.0 bioparticles/L or body temperature greater than 37 stC)
- perioperative blood derivatives, steroids or non-steroidal anti-inflammatory drug (NSAID)

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02188407
Slovenia | |
UMCLjubljana, CD of Anaesthesiology and Intensive Therapy | |
Ljubljana, Slovenia, 1230 |
Principal Investigator: | Iztok Potocnik, MD, MSC | University Medical Centre Ljubljana | |
Study Chair: | Vesna Novak Jankovic, MD, PROF | University Medical Centre Ljubljana |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Iztok Potocnik, MD, MSC, University Medical Centre Ljubljana |
ClinicalTrials.gov Identifier: | NCT02188407 |
Other Study ID Numbers: |
UKC-TOR-1 |
First Posted: | July 11, 2014 Key Record Dates |
Last Update Posted: | July 11, 2014 |
Last Verified: | July 2014 |
thoracotomy one-lung ventilation (OLV) total intravenous anaesthesia (TIVA) |
volatile induced and maintained anaesthesia (VIMA) cytokines interleukine (IL) |
Inflammation Pathologic Processes Propofol Sevoflurane Hypnotics and Sedatives Central Nervous System Depressants |
Physiological Effects of Drugs Anesthetics, Intravenous Anesthetics, General Anesthetics Platelet Aggregation Inhibitors Anesthetics, Inhalation |